Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | GFER | P55789 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7792404 | 0.98 | ALDH1A1 (0.67) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL11494791 | 0.88 | KDM4E (0.55) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL8354133 | 0.85 | ALDH1A1 (0.70) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL21650991 | 0.84 | ALDH1A1 (0.59) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL16572388 | 0.83 | ALDH1A1 (0.68) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL5510459 | 0.83 | ALDH1A1 (0.68) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL8305793 | 0.83 | ALDH1A1 (0.63) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL13039128 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL13039127 | 0.83 | ALDH1A1 (0.50) | ALDH1A1GFERKDM4EL3MBTL1KMT2A | |
| SCHEMBL13079103 | 0.82 | ALDH1A1 (0.69) | ALDH1A1GFERKDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006050476-A2 | PYRIMIDINE DERIVATIVES AS ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | ALDH1A1 3516/4885GFER 3601/4885KDM4E 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.